A Phase 1 interventional study of AZD9291 in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-21.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to evaluate the pharmacokinetic and Mass Balance of single dose [14C] AZD9291 in healthy male volunteers
A Single-centre, Non-Randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD9291 in Healthy Male Volunteers
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
1, Volunteers must be willing to use reliable methods of (condom and spermicide), even if their partners are , surgically sterile, or using an effective hormonal method of contraception or intrauterine coil. 2. In addition, volunteers must agree to continue to take similar contraceptive precautions until 6 months after the last administration of AZD9291 and avoid procreative sex as well as sperm donation for 6 months.
Exclusion Criteria: 1, Any abnormalities in physical examination, vital signs, hematology,clinical chemistry, urinalysis or at baseline in the opinion of the investigator. 2. Radiation exposure from clinical studies, including that from the present study, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. -
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Volunteers will receive 20 mg \[14C\]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
Drug: AZD9291
Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
Percentage of Radioactive Dose of [14C] Radiolabelled AZD9291 Recovered in Urine, Faeces, and in Total.
The percentage of radioactive dose of \[14C\] radiolabelled AZD9291 recovered in urine, faeces, and in total, up to Day 85.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992. Urine (h): 0-4, 4-8, 8-12, 12-24, every 24 hrs to 504, 648-72, 816-40, 984-1008 and 1992-2016. Faeces: 0-24h and then as per urine.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration AUC(0-t)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-t), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Area Under the Concentration-time Curve From Time Zero to the Time of 72 Hours AUC(0-72)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of 72 hours AUC(0-72), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Area Under the Concentration-time Curve From Time Zero to 24 Hours AUC(0-24)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of 24 hours AUC(0-24), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Maximum Plasma Concentration (Cmax)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Time to Cmax (Tmax)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of by assessment of time to Cmax (tmax), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Lag Time Before Observation of Quantifiable Analyte Concentrations (Tlag)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of lag time before observation of quantifiable analyte concentrations (tlag), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291 Plasma, Whole Blood and Plasma [14C] Radioactivity by Assessment of Apparent Oral Clearance (CL/F)
Pharmacokinetics of AZD9291 plasma, whole blood and plasma \[14C\] radioactivity by assessment of apparent oral clearance (CL/F), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291 Plasma, Whole Blood and Plasma [14C] Radioactivity by Assessment of Apparent Volume of Distribution (Vz/F)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of apparent volume of distribution (Vz/F), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Elimination Half-life (t1/2,λz)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of elimination half-life (t1/2,λz), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Elimination Rate Constant (λz)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of elimination rate constant (λz), derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of AUC Metabolite to Parent Ratio, AZ7550 or AZ5104 AUC/AZD9291 AUC Adjusted for Differences in Molecular Weight (M/PAUC)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC metabolite to parent ratio, AZ7550 or AZ5104 AUC/AZD9291 AUC adjusted for differences in molecular weight (M/PAUC), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Cmax Metabolite to Parent Ratio, AZ7550 or AZ5104 (M/PCmax)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax metabolite to parent ratio, AZ7550 or AZ5104 (M/PCmax), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Cmax Ratio of Plasma AZD9291, AZ7550 or AZ5104 (PL) to Plasma Radioactivity (Cmax(PL)/Cmax(PR))
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax ratio of plasma AZD9291, AZ7550 or AZ5104 (PL) to plasma radioactivity (Cmax(PL)/Cmax(PR)), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Cmax Ratio of Whole Blood Radioactivity (WBR) to PR Cmax (WBR)/Cmax(PR)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax ratio of whole blood radioactivity (WBR) to PR Cmax (WBR)/Cmax(PR), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of AUC Ratio of Plasma AZD9291, AZD7550 or AZD5104 (PL) to Plasma Radioactivity (PR) AUC(PL)/AUC(PR)
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC ratio of plasma AZD9291, AZD7550 or AZD5104 (PL) to plasma radioactivity (PR) AUC(PL)/AUC(PR), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of AUC Ratio of WBR to PR (AUC(WBR)/AUC(PR))
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC ratio of WBR to PR (AUC(WBR)/AUC(PR)), derived from the curves taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Area Under the Concentration-time Curve AUC
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve AUC, derived from the curve taken during the treatment period.
Time frame: Blood samples (hrs) - 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, every 24 to 168, 336, 504, 648, 816, 904 and 1992.
Pharmacokinetics of AZD9291, Its Metabolites and Urine [14C] Total Radioactivity by Assessment of Urine Concentration or Concentration Equivalent x Urine Volume (Aeu)
Pharmacokinetics of AZD9291, its metabolites and urine \[14C\] total radioactivity by assessment of urine concentration or concentration equivalent x urine volume (Aeu), derived from the curve taken during the treatment period.
Time frame: Urine (h): 0-4, 4-8, 8-12, 12-24, every 24 hrs to 504, 648-72, 816-40, 984-1008 and 1992-2016.
Pharmacokinetics of AZD9291 and Urine [14C] Total Radioactivity by Assessment of Percentage (or Fraction) of Actually Administered Dose / Radioactivity (Feu)
Pharmacokinetics of AZD9291 and urine \[14C\] total radioactivity by assessment of percentage (or fraction) of actually administered dose / radioactivity (feu), derived from the curve taken during the treatment period.
Time frame: Urine (h): 0-4, 4-8, 8-12, 12-24, every 24 hrs to 504, 648-72, 816-40, 984-1008 and 1992-2016.
8 subjects were recruited into the study, as anticipated in the protocol. All received treatment with 20 mg \[14C\]-AZD9291 oral solution (free base equivalent) containing a nominal dose 1 μCi (0.037 MBq) activity as a single administration on Day 1 and all completed the study.
| Milestone | AZD9291 20mg |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
The percentage of radioactive dose of \[14C\] radiolabelled AZD9291 recovered in urine, faeces, and in total, up to Day 85.
| Percentage radioactive dose recovered | AZD9291 20mg |
|---|---|
| Urine | 14.2 ± 2.08 |
| Faeces | 67.8 ± 4.35 |
| Total | 81.9 ± 4.41 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-t), derived from the curve taken during the treatment period.
| nM*h | AZD9291 20mg |
|---|---|
| AZD9291 | 1580 ± 17.7 |
| AZ5104 | 125 ± 17.4 |
| AZ7550 | 113 ± 15.6 |
| [14C] plasma | 178000 ± 15.2 |
| [14C] blood | 158000 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of 72 hours AUC(0-72), derived from the curve taken during the treatment period.
| nM*h | AZD9291 20mg |
|---|---|
| AZD9291 | 1010 ± 17.7 |
| AZ5104 | 72.1 ± 17.4 |
| AZ7550 | 50.9 ± 15.6 |
| [14C] plasma | 9670 ± 15.2 |
| [14C] blood | 10700 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve from time zero to the time of 24 hours AUC(0-24), derived from the curve taken during the treatment period.
| nM*h | AZD9291 20mg |
|---|---|
| AZD9291 | 444 ± 17.7 |
| AZ5104 | 24.4 ± 17.4 |
| AZ7550 | 15.7 ± 15.6 |
| [14C] plasma | 1980 ± 15.2 |
| [14C] blood | 2300 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.
| nM | AZD9291 20mg |
|---|---|
| AZD9291 | 29.9 ± 17.7 |
| AZ5104 | 1.41 ± 17.4 |
| AZ7550 | .957 ± 15.6 |
| [14C] plasma | 217 ± 15.2 |
| [14C] blood | 260 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of by assessment of time to Cmax (tmax), derived from the curve taken during the treatment period.
| hours | AZD9291 20mg |
|---|---|
| AZD9291 | 6 ± 17.7 |
| AZ5104 | 6 ± 17.4 |
| AZ7550 | 36 ± 15.6 |
| [14C] plasma | 144 ± 15.2 |
| [14C] blood | 132.02 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of lag time before observation of quantifiable analyte concentrations (tlag), derived from the curve taken during the treatment period.
| hours | AZD9291 20mg |
|---|---|
| AZD9291 | 0 ± 17.7 |
| AZ5104 | .51 ± 17.4 |
| AZ7550 | .76 ± 15.6 |
| [14C] plasma | 0 ± 15.2 |
| [14C] blood | .25 ± 12.8 |
Pharmacokinetics of AZD9291 plasma, whole blood and plasma \[14C\] radioactivity by assessment of apparent oral clearance (CL/F), derived from the curve taken during the treatment period.
| L/h | AZD9291 20mg |
|---|---|
| AZD9291 | 26.7 ± 17.7 |
| [14C] plasma | .213 ± 15.2 |
| [14C] blood | .231 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of apparent volume of distribution (Vz/F), derived from the curve taken during the treatment period.
| L | AZD9291 20mg |
|---|---|
| AZD9291 | 2260 ± 17.7 |
| [14C] plasma | 146 ± 15.2 |
| [14C] blood | 191 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of elimination half-life (t1/2,λz), derived from the curve taken during the treatment period.
| hour | AZD9291 20mg |
|---|---|
| AZD9291 | 61.2 ± 17.7 |
| AZ5104 | 55.2 ± 17.4 |
| AZ7550 | 82 ± 15.6 |
| [14C] plasma | 474 ± 15.2 |
| [14C] blood | 562 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of elimination rate constant (λz), derived from the curve taken during the treatment period.
| 1/h | AZD9291 20mg |
|---|---|
| AZD9291 | .0115 ± 17.7 |
| AZ5104 | .0129 ± 17.4 |
| AZ7550 | .00854 ± 15.6 |
| [14C] plasma | .00147 ± 15.2 |
| [14C] blood | .00125 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC metabolite to parent ratio, AZ7550 or AZ5104 AUC/AZD9291 AUC adjusted for differences in molecular weight (M/PAUC), derived from the curves taken during the treatment period.
| Ratio | AZD9291 20mg |
|---|---|
| AZ5104 | .0909 ± 17.4 |
| AZ7550 | .0848 ± 15.6 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax metabolite to parent ratio, AZ7550 or AZ5104 (M/PCmax), derived from the curves taken during the treatment period.
| ratio | AZD9291 20mg |
|---|---|
| AZ5104 | .0471 ± 17.4 |
| AZ7550 | .0319 ± 15.6 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax ratio of plasma AZD9291, AZ7550 or AZ5104 (PL) to plasma radioactivity (Cmax(PL)/Cmax(PR)), derived from the curves taken during the treatment period.
| ratio | AZD9291 20mg |
|---|---|
| AZD9291 | .138 ± 17.7 |
| AZ5104 | .00648 ± 17.4 |
| AZ7550 | .0044 ± 15.6 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of Cmax ratio of whole blood radioactivity (WBR) to PR Cmax (WBR)/Cmax(PR), derived from the curves taken during the treatment period.
| ratio | AZD9291 20mg |
|---|---|
| Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of Cmax Ratio of Whole Blood Radioactivity (WBR) to PR Cmax (WBR)/Cmax(PR) | 1.2 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC ratio of plasma AZD9291, AZD7550 or AZD5104 (PL) to plasma radioactivity (PR) AUC(PL)/AUC(PR), derived from the curves taken during the treatment period.
| ratio | AZD9291 20mg |
|---|---|
| AZD9291 | .00826 ± 17.4 |
| AZ5104 | .000751 ± 15.6 |
| AZ7550 | .000698 ± 15.2 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of AUC ratio of WBR to PR (AUC(WBR)/AUC(PR)), derived from the curves taken during the treatment period.
| ratio | AZD9291 20mg |
|---|---|
| Pharmacokinetics of AZD9291, Its Metabolites and Whole Blood and Plasma [14C] Radioactivity by Assessment of AUC Ratio of WBR to PR (AUC(WBR)/AUC(PR)) | .917 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and whole blood and plasma \[14C\] radioactivity by assessment of area under the concentration-time curve AUC, derived from the curve taken during the treatment period.
| nM*h | AZD9291 20mg |
|---|---|
| AZD9291 | 1590 ± 17.7 |
| AZ5104 | 143 ± 17.4 |
| AZ7550 | 132 ± 15.6 |
| [14C] plasma | 190000 ± 15.2 |
| [14C] blood | 174000 ± 12.8 |
Pharmacokinetics of AZD9291, its metabolites and urine \[14C\] total radioactivity by assessment of urine concentration or concentration equivalent x urine volume (Aeu), derived from the curve taken during the treatment period.
| nmol | AZD9291 20mg |
|---|---|
| AZD9291 | 329 ± 133 |
| AZ5104 | 167 ± 85.8 |
| AZ7550 | 184 ± 75.4 |
| [14C] urine | 3870 ± 673 |
Pharmacokinetics of AZD9291 and urine \[14C\] total radioactivity by assessment of percentage (or fraction) of actually administered dose / radioactivity (feu), derived from the curve taken during the treatment period.
| Percentage of administered dose | AZD9291 20mg |
|---|---|
| AZD9291 | .823 ± .332 |
| AZ5104 | .416 ± .214 |
| AZ7550 | .460 ± .189 |
| [14C] urine | 9.67 ± 1.69 |
Collected over From screening through to day 85 (end of study). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9291 20mg | — | 0/8 (0%) | 7/8 (87.5%) |
| Event | AZD9291 20mg |
|---|---|
| HeadacheNervous system disorders | 2/8 |
| AsthenopiaEye disorders | 1/8 |
| Visual impairmentEye disorders | 1/8 |
| Abdominal pain upperGastrointestinal disorders | 1/8 |
| ConstipationGastrointestinal disorders | 1/8 |
| NauseaGastrointestinal disorders | 1/8 |
| Non-cardiac chest painGeneral disorders | 1/8 |
| Otitis mediaInfections and infestations | 1/8 |
| LacerationInjury, poisoning and procedural complications | 1/8 |
| Back painMusculoskeletal and connective tissue disorders | 1/8 |
| Age, Continuous(Years) | AZD9291 20mg |
|---|---|
| Mean | 42 ± 13 |
| Sex: Female, Male(Participants) | AZD9291 20mg |
|---|---|
| Female | 0 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | AZD9291 20mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | AZD9291 20mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
The record gives a start of May 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib